The potential role of complement alternative pathway activation in hypertensive renal damage

Area of Science:

• Nephrology
• Immunology
• Cardiovascular Medicine

Background:

• Hypertensive renal damage is a frequent secondary kidney disease linked to uncontrolled hypertension.
• Abnormal activation of the complement alternative pathway (AP) is increasingly recognized in hypertensive individuals and animal models.
• Factors like high renin, reduced factor H binding, and local complement protein synthesis may drive kidney AP activation during hypertension.

Purpose of the Study:

• To investigate the role of complement alternative pathway (AP) activation in the pathogenesis of hypertensive renal damage.
• To evaluate the therapeutic potential of complement inhibition in mitigating kidney damage associated with hypertension.

Main Methods:

• Review of recent evidence on complement AP activation in hypertensive patients and animal models.
• Analysis of factors promoting AP activation in the hypertensive kidney.
• Examination of the effects of AP activation products on renal cells and immune responses.
• Assessment of existing clinical and preclinical data on complement inhibition strategies.

Main Results:

• Complement AP activation products contribute to mesangial and tubular cell transitions, endothelial cell damage, and immune cell recruitment, exacerbating hypertensive renal damage.
• Clinical data suggest benefits of C5 monoclonal antibody in malignant hypertension.
• Pharmacological complement inhibition in hypertensive animal models has shown limited efficacy in improving kidney function.

Conclusions:

• The precise role of the complement AP in hypertensive renal damage pathogenesis requires further elucidation.
• The therapeutic value of complement inhibition for hypertensive renal damage remains uncertain and warrants additional investigation.